Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 10 years, with Sep 2025 value amounting to $367.4 million.

  • Arrowhead Pharmaceuticals' Other Non-Current Liabilities rose 7.63% to $367.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $367.4 million, marking a year-over-year increase of 7.63%. This contributed to the annual value of $367.4 million for FY2025, which is 7.63% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $367.4 million for Q3 2025, which was up 1.98% from $360.3 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $367.4 million in Q3 2025 and a low of $252.8 million during Q4 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $336.0 million (2024), whereas its average is $313.5 million.
  • Data for Arrowhead Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY increased of 27.74% (in 2024) over the last 5 years.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $252.8 million in 2022, then increased by 8.24% to $273.7 million in 2023, then grew by 26.70% to $346.8 million in 2024, then grew by 7.63% to $367.4 million in 2025.
  • Its Other Non-Current Liabilities was $367.4 million in Q3 2025, compared to $360.3 million in Q2 2025 and $352.3 million in Q1 2025.